Luna stack (nasal for women)
Calm + Lift — two nasal sprays (for women)
2.394.000 ₫
Vial-by-vial breakdown
Two dose-engineered nasal sprays formulated for relief of PMDD-style luteal-phase symptoms in women — anxiety, low mood, social withdrawal and emotional dysregulation in the week before menstruation. Calm pairs Selank with oxytocin for anxiolytic and bonding support; Lift pairs Semax with oxytocin for focus, drive and social engagement. Each 5mL bottle is mixed from one full peptide vial plus one full oxytocin vial in saline, delivering ~50 sprays at clean, repeatable doses. Calm (5mL): 10mg Selank + 2mg oxytocin in saline → 200µg Selank + 40µg oxytocin per spray. Administer before bed. Lift (5mL): 10mg Semax + 2mg oxytocin in saline → 200µg Semax + 40µg oxytocin per spray. Administer in the morning. Spray-only. 10% stack discount applied.
Dosage
Calm: 1 spray daily before bed → Selank 200µg + Oxytocin 40µg. Lift: 1 spray daily in the morning → Semax 200µg + Oxytocin 40µg. ~50 sprays per 5mL bottle.
Key Features
- Calm spray: Selank + Oxytocin
- Lift spray: Semax + Oxytocin
- 4 vials, mixed into 2 sprays
- 10% stack discount
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Walsh et al., Frontiers in Psychiatry (2018)
Clinical Research
Randomised placebo-controlled pilot in women with PMDD: intranasal oxytocin (40 IU) during the late luteal phase reduced premenstrual depression, anger, and anxiety symptoms versus placebo — the only completed interventional trial of oxytocin in PMDD to date.
Read full studyAdditional Research
Source: Semenova et al. (2008)
Open clinical trial in 62 patients with generalised anxiety disorder: intranasal Selank matched medazepam on the Hamilton Anxiety scale across two weeks of treatment, without sedation, cognitive impairment, or dependence — supporting an anxiolytic profile suitable for daytime use.
Read full studySource: Yang et al., Frontiers in Endocrinology (2022)
Narrative review of oxytocin across the menstrual cycle: endogenous oxytocin tone drops in the late luteal phase as estrogen falls and oxytocin-receptor sensitivity declines, providing a mechanistic basis for cyclical mood symptoms in PMDD and for luteal-phase oxytocin supplementation.
Read full studyHuman Clinical Trials
- Intranasal oxytocin in autismNew England Journal of Medicine · 2021
24-week trial in 290 children and adolescents: no significant benefit over placebo on the main social outcome.
A negative result — included for balance.
Read the trial290participants